 Actively personalized vaccination trial for newly diagnosed glioblastomaNorbert Hilf,
Sabrina Kuttruff-Coqui,
Katrin Frenzel,
Valesca Bukur,
Stefan Stevanović,
Cécile Gouttefangeas,
Michael Platten,
Ghazaleh Tabatabai,
Valerie Dutoit,
Sjoerd H. Burg,
Per thor Straten,
Francisco Martínez-Ricarte,
Berta Ponsati,
Hideho Okada,
Ulrik Lassen,
Arie Admon,
Christian H. Ottensmeier,
Alexander Ulges,
Sebastian Kreiter,
Andreas Deimling,
Marco Skardelly,
Denis Migliorini,
Judith R. Kroep,
Manja Idorn,
Jordi Rodon,
Jordi Piró,
Hans S. Poulsen,
Bracha Shraibman,
Katy McCann,
Regina Mendrzyk,
Martin Löwer,
Monika Stieglbauer,
Cedrik M. Britten,
David Capper,
Marij J. P. Welters,
Juan Sahuquillo,
Katharina Kiesel,
Evelyna Derhovanessian,
Elisa Rusch,
Lukas Bunse,
Colette Song,
Sandra Heesch,
Claudia Wagner,
Alexandra Kemmer-Brück,
Jörg Ludwig,
John C. Castle,
Oliver Schoor,
Arbel D. Tadmor,
Edward Green,
Jens Fritsche,
Miriam Meyer,
Nina Pawlowski,
Sonja Dorner,
Franziska Hoffgaard,
Bernhard Rössler,
Dominik Maurer,
Toni Weinschenk,
Carsten Reinhardt,
Christoph Huber,
Hans-Georg Rammensee,
Harpreet Singh-Jasuja,
Ugur Sahin,
Pierre-Yves Dietrich and
Wolfgang Wick ()
Nature, 2019, vol. 565, issue 7738, 240-245 Abstract: Abstract Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors1,2. For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neoepitopes are thought to be essential3. There is limited intratumoural infiltration of immune cells4 in glioblastoma and these tumours contain only 30–50 non-synonymous mutations5. Exploitation of the full repertoire of tumour antigens—that is, both unmutated antigens and neoepitopes—may offer more effective immunotherapies, especially for tumours with a low mutational load. Here, in the phase I trial GAPVAC-101 of the Glioma Actively Personalized Vaccine Consortium (GAPVAC), we integrated highly individualized vaccinations with both types of tumour antigens into standard care to optimally exploit the limited target space for patients with newly diagnosed glioblastoma. Fifteen patients with glioblastomas positive for human leukocyte antigen (HLA)-A*02:01 or HLA-A*24:02 were treated with a vaccine (APVAC1) derived from a premanufactured library of unmutated antigens followed by treatment with APVAC2, which preferentially targeted neoepitopes. Personalization was based on mutations and analyses of the transcriptomes and immunopeptidomes of the individual tumours. The GAPVAC approach was feasible and vaccines that had poly-ICLC (polyriboinosinic-polyribocytidylic acid-poly-l-lysine carboxymethylcellulose) and granulocyte–macrophage colony-stimulating factor as adjuvants displayed favourable safety and strong immunogenicity. Unmutated APVAC1 antigens elicited sustained responses of central memory CD8+ T cells. APVAC2 induced predominantly CD4+ T cell responses of T helper 1 type against predicted neoepitopes. Date: 2019 Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:565:y:2019:i:7738:d:10.1038_s41586-018-0810-y Ordering information: This journal article can be ordered from DOI: 10.1038/s41586-018-0810-y Access Statistics for this article Nature is currently edited by Magdalena Skipper More articles in Nature from Nature |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.